bioRxiv Science⌕ Search

Biology subjects

Fleischman, A. G.

Publications and source records attributed to Fleischman, A. G..

6 recordsLinked to original sources

Hierarchical tissue structure creates history-dependent barriers to clonal invasion

Tissues of higher organisms are maintained by hierarchies of stem and progenitor cell compartments regulated by homeostatic feedback. Somatic mutations generate genetically distinct clones whose evolutionary success depends not only on their fitness but also on the tissue architecture in which they arise. In previous work, we showed that this hierarchical organization creates invasion barriers that prevent advantageous mutants originating in downstream compartments from expanding unless their fitness exceeds a critical threshold. Here, we extend this framework to populations containing multiple competing mutant clones. We derive a general invasion criterion showing that the threshold for mutant expansion is determined by the equilibrium established by the resident clones and therefore depends on the evolutionary history of the system. Established clones modify the invasion barriers encountered by subsequent mutants, making clonal evolution history-dependent. The theory predicts competitive exclusion between clones entering the same compartment and shows that resident clones can prevent the establishment of later mutants. Using a model previously parameterized for murine hematopoiesis, we showed that our framework provides a mechanistic explanation for mutation-order effects involving JAK2 V617F and TET2 mutations in myeloproliferative neoplasms. Our results identify invasion barriers as a principle governing history-dependent clonal evolution in hierarchical tissues.

evolutionary biology↗

Cigarette Smoke and E-Cigarette Aerosol Extracts Induce Myelopoiesis and Suppress Inflammatory Cytokine Production

Tobacco and nicotine use remain the leading preventable drivers of cancer risk, and both direct and secondhand exposure to combustible cigarettes or electronic nicotine devices perturbs immune function and hematopoiesis. Here, we evaluate the impact of e-cigarette vapor and combustible cigarette smoke on in vitro cell inflammatory responses and in vivo long-term hematopoietic differentiation. In cell-based studies, cigarette smoke extract (CSE) and e-cigarette vapor extract (EVE) consistently suppress LPS-induced TNF- secretion across macrophage/monocyte models, including primary mouse and human cells and complementary cell lines, indicating a reproducible immunosuppressive effect on mature myeloid cells. Brief ex vivo exposure to CSE also alters myeloid subset composition and modifies the proliferative behavior of Tet2-knockout cells, suggesting that smoke-related cues can reshape competitive dynamics among mutant and wild-type myeloid progenitors. To assess consequences of smoking behavior in vivo, we used a custom nose-cone inhalation system to deliver controlled exposures to combustible cigarette smoke or e-cigarette aerosol to mice. Chronic exposure increased myeloid proliferation, consistent with smoking behavior inducing premature aging of the hematopoietic stem cell pool. Thus, these studies support a model in which tobacco exposures blunt innate immune responsiveness while simultaneously driving myeloid expansion conditions that accelerate hematopoietic aging.

cancer biology↗

Pitavastatin counteracts venetoclax resistance mechanisms in acute myeloid leukemia

The BCL2 inhibitor venetoclax has therapeutic activity in several hematological malignancies. In acute myeloid leukemia (AML), venetoclax combined with hypomethylating agents is the standard of care for patients unfit for intensive chemotherapy, but intrinsic and acquired resistance are common. Loss of p53 function is strongly associated with venetoclax resistance, and adding venetoclax to 5-azacitidine provides no overall survival benefit in TP53-mutant AML. Other frequent mechanisms of venetoclax resistance in AML include FLT3 mutations, MCL-1 upregulation, and altered mitochondrial metabolism. Unfortunately, it has been challenging to develop agents that target these mechanisms directly and combinatorially. Here we report that pitavastatin, an inhibitor of HMG-CoA-reductase, promotes apoptosis and overcomes several venetoclax resistance mechanisms in human AML cells. At clinically achievable concentrations, pitavastatin treatment has potent cytotoxic activity in cells with mutations in TP53 or FLT3. The apoptotic mechanism involves p53-independent PUMA upregulation and reduced MCL-1 expression. Pitavastatin also suppresses mitochondrial gene expression and oxidative metabolism. The pro-apoptotic actions of pitavastatin depend on depletion of geranylgeranyl pyrophosphate (GGPP) and can be recapitulated by inhibiting GGPP synthase or geranylgeranyltransferase-1 enzymes. These results provide a mechanistic rationale for adding pitavastatin to AML regimens to prevent or overcome venetoclax resistance.

cancer biology↗

Multimodal gene and targeted drug therapy for chronic myelogenous leukemia: Computational target analysis and therapeutic validation

Developing an efficient and safe therapy necessitates a mechanistic understanding of the complex underlying pathology and manipulation of the multiple pathways at the molecular and genetic level. Network-based simulation of chronic myeloid leukemia (CML), a relatively well-understood cancer model, revealed the dynamics of simultaneously expressing pro-apoptotic BIM and silencing pro-survival MCL-1 in combination with the BCR-ABL-targeted tyrosine kinase inhibitor dasatinib. Viral/nonviral chimeric nanoparticles (ChNPs) composed of a BIM-expressing adeno-associated virus (AAV) core and a degradable polymeric shell that encapsulates MCL-1 siRNA (BIM/MCL-1 ChNPs) synergistically and selectively killed BCR-ABL+ CML cells in combination with dasatinib. In a mouse CML model, the BIM/MCL-1 ChNPs and dasatinib combination therapy suppressed proliferation of BCR-ABL+ hematopoietic cells and prevented leukemic infiltration of organs. The synergistic anti-leukemic effect was further pronounced in an acute phase model of the disease. This study investigated a strategy of developing a versatile and tunable multimodal therapy assisted by a computational toolset that analyzes the molecular foundation of a disease and predicts therapeutic response. The interdisciplinary approach developed and validated in this study can be used in discovering new therapies for cancer and other diseases. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=182 SRC="FIGDIR/small/656072v1_ufig1.gif" ALT="Figure 1"> View larger version (43K): org.highwire.dtl.DTLVardef@1e3632borg.highwire.dtl.DTLVardef@1839f12org.highwire.dtl.DTLVardef@4060c0org.highwire.dtl.DTLVardef@8ff0de_HPS_FORMAT_FIGEXP M_FIG O_FLOATNOGraphical abstractC_FLOATNO summarizing the study design and approach. A schematic representation of the integrated in silico and in vivo pipeline utilized in the study. The workflow begins with in silico simulations, including Boolean network modeling and protein-protein interaction (PPI) network analyses, leading to target discovery, optimized nanoparticle design, and validation in pathological contexts. This was followed by therapeutic efficacy assessments of BIM/MCL-1 ChNPs and their combination with dasatinib in BCR-ABL+ leukemia models in vitro and in vivo. C_FIG

cancer biology↗

Dynamically adjusted cell fate decisions and resilience to mutant invasion during steady state hematopoiesis revealed by an experimentally parameterized mathematical model

A major next step in hematopoietic stem cell (HSC) biology is to obtain a thorough quantitative understanding of cellular and evolutionary dynamics involved in undisturbed hematopoiesis. Mathematical models are key in this respect, and are most powerful when parameterized experimentally and containing sufficient biological complexity. Mathematical models of hematopoiesis have either been parameterized experimentally without non-linear dynamics, or they include these complexities but have not been parameterized to the same extent. We bridge this gap using mouse data to parameterize a mathematical model of hematopoiesis that includes homeostatic control mechanisms as well as clonal evolution. We find that non-linear feedback control drastically changes the interpretation of kinetic estimates at homeostasis. This suggests that short-term HSC and multipotent progenitors (MPPs) can dynamically adjust to sustain themselves in the absence of long-term HSCs, even if they differentiate more often than they self-renew in undisturbed homeostasis. Additionally, the presence of feedback control in the model renders the system resilient against mutant invasion. Invasion barriers, however, can be overcome by a combination of age-related changes in stem cell differentiation and a mutant-associated inflammatory environment. This helps us understand the evolution of e.g. TET2, DNMT3A, or JAK2 mutants, and how to potentially reduce mutant burden.

evolutionary biology↗

Characterizing the microbiome of patients with myeloproliferative neoplasms during a Mediterranean diet intervention

Myeloproliferative neoplasms (MPN) are a class of hematological malignancies which result in the overproduction of myeloid lineage cells. These malignancies result in increased cytokine production and inflammation, which correlate with worsened symptom burden and prognosis. Other than bone marrow transplantation, there is no cure for myeloproliferative neoplasms. As such, treatments focus on reducing thrombotic risk, inflammation, and symptom burden. Because current pharmacological treatments carry significant side-effects, there is a need to explore low-risk therapies. One alternative is the Mediterranean diet, which is rich in anti-inflammatory foods, reduces inflammatory biomarkers, and beneficially alters the gut microbiome. Here, we performed a 15-week clinical trial of 28 individuals with MPN who were randomized to dietary counseling based on either a Mediterranean diet or standard U.S. Guidelines for Americans. Our primary objective was to determine if MPN patients were able to adopt a Mediterranean eating style when supported with dietician counseling. As exploratory endpoints, we investigated the impact of diet and inflammation on the gut microbiome. Using shotgun metagenomic sequencing, we found that microbiome diversity and composition were stable throughout the study duration in both cohorts. Furthermore, we discovered significant differences in the microbiomes between MPN subtypes, such as increased beta-dispersion in subjects with myelofibrosis. Lastly, we found several significant correlations between the abundances of multiple bacterial taxa and cytokine levels. Together, this study provides insight into the interaction between diet, inflammation, and the gut microbiome. ImportanceThe gut microbiome serves as an interface between the host and diet. Diet and the gut microbiome both play important roles in managing inflammation, which is a key aspect of MPN. Studies have shown that a Mediterranean diet can reduce inflammation. Therefore, we longitudinally characterized the gut microbiomes of MPN patients in response to Mediterranean or US-style dietary counseling to determine whether there were microbiome-associated changes in inflammation. We did not find significant changes in the gut microbiome associated with diet, but we did find several associations with inflammation. This research paves the way for future studies by identifying potential mechanistic targets implicated in inflammation within the MPN gut microbiome.

microbiology↗